Guest editorial: Vasopressin: The neglected target for stress modulation?

Stress and Health

Volumn 21, Issue 3, 2005, Pages 145-146

  Dinan, Timothy G ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR; NORADRENALIN; SEROTONIN; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V3 RECEPTOR;

ADDISON DISEASE; ADRENERGIC SYSTEM; BRAIN FUNCTION; BRAIN NERVE CELL; CORTICOTROPIN RELEASE; DRUG TARGETING; EDITORIAL; ENDOCRINE FUNCTION; HORMONE ACTION; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MENTAL STRESS; MODULATION; NEUROANATOMY; NEUROENDOCRINE SYSTEM; NONHUMAN; PHYSICAL STRESS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN LOCALIZATION; STRESS; THALAMUS MIDLINE NUCLEUS;

EID: 24644444827     PISSN: 15323005     EISSN: None     Source Type: Journal    
DOI: 10.1002/smi.1054     Document Type: Editorial

References (11)

1. Aguilera, G. (1994). Regulation of pituitary ACTH secretion during chronic stress. Frontiers in Neuroendocrinology, 15, 321-350.
2. Dinan, T.G. (1994). Glucocorticoids and the genesis of depression: A psychobiological model. British Journal of Psychiatry, 164, 365-371.
3. 3 receptor responses in melancholic depression. Psychological Medicine, 34, 169-172.
4. Dinan, T.G., Lavelle, E., Scott, L.V., Newell-Price, J., Medbak, S., & Grossman, A.B. (1999). Desmopressin normalises the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: Evidence of enhanced vasopressinergic responsivity. Journal of Clinical Endocrinology and Metabolism, 84, 2238-2240.
5. Gold, P.W., Chrousos, G.P. (1985). Clinical studies with corticotropin releasing factor: Implications for the diagnosis and pathophysiology of depression, Cushing's disease and adrenal insufficiency. Psychoneuroendocrinology, 10, 401-419.
6. Griebel, G., Simiand, J., Serrandeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.P., & Soubrie, P. (2002). Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proceedings of the National Academy of Science (USA), 30, 6370-6375.
7. Keck, M.E., Wigger A., Welt, T., Muller, M.B., Gesing, A., Reul, J.M., & Holsboer, F. (2002). Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: Implications for the pathogenesis of affective disorders. Neuropsychopharmacology, 26, 94-105.
8. McEwen, B.S., Davis, P., Parsons, B., & Pfaff, D. (1979). The brain as target for steroid hormones. Annual Review of Neuroscience, 2, 65-112.
9. Nemeroff, C.B., Widerlov, E., & Bissette, G. (1996). Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science, 226, 1342-1344.
10. Raadsheer, F.C., Hoogendijk, W.J.G., Stam, F.C., Tilders, F.J.H., & Swaab, D.F. (1994). Increased number of corticotropin-releasing hormone neurons in the hypothalamic paraventricular nuclei of depressed patients. Neuroendocrinology, 60, 436-444.
11. Scott, L.V., & Dinan, T.G. (1997). The role of vasopressin in the regulation of the hypothalamic-pituitary-adrenal axis. Life Sciences, 62, 1985-1998.